Compare MTLS & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTLS | VNDA |
|---|---|---|
| Founded | 1990 | 2002 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 431.6M | 361.4M |
| IPO Year | 2014 | 2005 |
| Metric | MTLS | VNDA |
|---|---|---|
| Price | $7.77 | $5.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.90 |
| AVG Volume (30 Days) | 153.0K | ★ 635.3K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | $6.38 | $21.35 |
| Revenue Next Year | $6.45 | $37.40 |
| P/E Ratio | $61.39 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $4.78 | $4.27 |
| 52 Week High | $7.97 | $9.91 |
| Indicator | MTLS | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 67.87 | 42.97 |
| Support Level | $6.37 | $4.94 |
| Resistance Level | N/A | $5.55 |
| Average True Range (ATR) | 0.24 | 0.18 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 80.61 | 17.14 |
Materialise NV is a provider of 3D-printed medical devices and software and a pioneer in additive manufacturing software and services. The company operates through three principal segments: Materialise Software, Materialise Medical, and Materialise Manufacturing, with the Materialise Medical segment generating maximum revenue. The Materialise Medical segment develops and delivers medical software solutions, medical devices, and related products and services; the Materialise Software segment develops and delivers additive manufacturing software solutions and related services; and the Materialise Manufacturing segment delivers 3D-printed products and related services. The company generates maximum revenue from the United States of America.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.